Ardelyx Inc. buy Saftman
Start price
15.12.23
/
50%
€5.22
Target price
15.12.24
-
Performance (%)
56.32%
End price
31.01.24
€8.16
Summary
This prediction ended on 31.01.24 with a price of €8.16. The BUY prediction by Saftman for Ardelyx Inc. saw massive gains of 56.32%. Saftman has 50% into this predictionArdelyx, Inc. is a biopharmaceutical company that focuses on the research, development, and commercialization of innovative medicines aimed at treating kidney and cardiovascular diseases. The company uses a unique approach to drug discovery, developing therapeutics that target ion channels and transporters, which play a critical role in regulating activities in the body. Ardelyx's lead product candidate, tenapanor, is being studied for the treatment of conditions such as hyperphosphatemia in patients with chronic kidney disease, irritable bowel syndrome with constipation, and diverticulosis. The company is listed on the NASDAQ exchange under the ticker symbol ARDX.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Ardelyx Inc. | 10.483% | 10.483% |
| iShares Core DAX® | 1.454% | 0.904% |
| iShares Nasdaq 100 | -0.913% | 3.463% |
| iShares Nikkei 225® | 2.355% | 3.830% |
| iShares S&P 500 | 0.283% | 2.639% |
Comments by Saftman for this prediction
In the thread Ardelyx Inc. diskutieren
Saftman hat das Wertpapier Ardelyx Inc. in seinem Wikifolio Langfristige Aufwärtstrends gekauft.